Stewart Abbot
Directeur Technique/Scientifique/R&D chez TURNSTONE BIOLOGICS CORP.
Fortune : - $ au 30/04/2024
Profil
Stewart Abbot is currently the Chief Scientific & Operating Officer at Adicet Therapeutics, Inc. and the Chief Scientific Officer at Turnstone Biologics Corp.
Previously, he held positions as the Senior Director-Research at Celgene Cellular Therapeutics, the Vice President-Translational Research at Fate Therapeutics, Inc., the SVP, Chief Operating & Scientific Officer at resTORbio, Inc., and the SVP, Chief Operating & Scientific Officer at Adicet Bio, Inc. Dr. Abbot obtained a doctorate degree from the University of London, an undergraduate degree from The University of Edinburgh, and a graduate degree from the University of Strathclyde.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 16/10/2023 | 0 ( -.--% ) | - $ | 30/04/2024 |
Postes actifs de Stewart Abbot
| Sociétés | Poste | Début |
|---|---|---|
| TURNSTONE BIOLOGICS CORP. | Directeur Technique/Scientifique/R&D | 01/06/2021 |
Adicet Therapeutics, Inc.
 Adicet Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Adicet Therapeutics, Inc. operates as a biopharmaceutical company focuses on the development of cell immunotherapies. It engages in the design and development of immunotherapies for cancer and other disease indications with a focus on novel universal immune cell therapies. The company was founded by Aya Jakobovits in 2014 and is headquartered in Beverly Hills, CA. | Directeur des opérations | 01/06/2018 |
Anciens postes connus de Stewart Abbot
| Sociétés | Poste | Fin |
|---|---|---|
| ADICET BIO, INC. | Directeur des opérations | 11/06/2021 |
| FATE THERAPEUTICS, INC. | Corporate Officer/Principal | 26/06/2018 |
| ADICET BIO, INC. | Directeur des opérations | - |
Celgene Cellular Therapeutics
 Celgene Cellular Therapeutics Pharmaceuticals: MajorHealth Technology Part of Bristol Myers Squibb Co., Celgene Cellular Therapeutics develops human pharmaceuticals. The company is based in Warren, NJ. The company was founded by Robert Joseph Hariri Gordon. | Corporate Officer/Principal | - |
Formation de Stewart Abbot
| The University of Edinburgh | Undergraduate Degree |
| University of London | Doctorate Degree |
| University of Strathclyde | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| FATE THERAPEUTICS, INC. | Health Technology |
| ADICET BIO, INC. | Health Technology |
| TURNSTONE BIOLOGICS CORP. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Celgene Cellular Therapeutics
Celgene Cellular Therapeutics Pharmaceuticals: MajorHealth Technology Part of Bristol Myers Squibb Co., Celgene Cellular Therapeutics develops human pharmaceuticals. The company is based in Warren, NJ. The company was founded by Robert Joseph Hariri Gordon. | Health Technology |
Adicet Therapeutics, Inc.
Adicet Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Adicet Therapeutics, Inc. operates as a biopharmaceutical company focuses on the development of cell immunotherapies. It engages in the design and development of immunotherapies for cancer and other disease indications with a focus on novel universal immune cell therapies. The company was founded by Aya Jakobovits in 2014 and is headquartered in Beverly Hills, CA. | Health Technology |
resTORbio, Inc.
 resTORbio, Inc. BiotechnologyHealth Technology resTORbio, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the development and commercialization of medicines for aging-related diseases and conditions. It offers an immunotherapy under the TORC1 program. The company was founded by Chen Schor and Joan Mannick on July 5, 2016 and is headquartered in Boston, MA. | Health Technology |
